Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Nanobiotix ADR Representing Ord Shs NBTX

Healthcare Biotechnology
Nanobiotix SA is a France-based nanomedicine company. The Company designs and manufactures nanoparticles that safely enhance the efficacy of radiation therapy in the treatment of cancer. It develops new tools for cancer that utilize a physical mode of action at the cellular level of the cancer cell. The Company's NanoXray technology comprises three products. Local treatment (surgery and... see more

Recent & Breaking News (NDAQ:NBTX)

Voting Rights and Shares Capital of the Company

GlobeNewswire September 13, 2023

NANOBIOTIX Strengthens Global Development Capabilities With the Appointment of Veteran Industry Leader Dr. Louis Kayitalire as Chief Medical Officer

GlobeNewswire September 5, 2023

NANOBIOTIX to Present at the H.C. Wainwright 25th Annual Global Investment Conference

GlobeNewswire August 31, 2023

NANOBIOTIX Announces Expiration of HSR Waiting Period Regarding the Agreement for Worldwide Co-Development and Commercialization of Potential First-in-Class Radioenhancer NBTXR3

GlobeNewswire August 15, 2023

NANOBIOTIX to Host Extraordinary General Meeting of Shareholders on September 1st, 2023

GlobeNewswire August 4, 2023

Voting Rights and Shares Capital of the Company

GlobeNewswire July 20, 2023

NANOBIOTIX Announces First Patient Injected in New Phase 1/2 Study Evaluating Radiotherapy-Activated NBTXR3 Plus Anti-PD-1 for Patients With Advanced Cancers

GlobeNewswire July 19, 2023

NANOBIOTIX Announces License Agreement for Worldwide Co-development and Commercialization of Potential First-In-Class Radioenhancer NBTXR3

GlobeNewswire July 10, 2023

Voting Rights and Shares Capital of the Company

GlobeNewswire June 8, 2023

NANOBIOTIX Provides First Quarter 2023 Operational and Financial Update

GlobeNewswire May 17, 2023

NANOBIOTIX Entering Final Contract Negotiations Following Agreement to Non-Binding Term Sheet for Development and Commercialization of NBTXR3 With a Major Global Pharmaceutical Company

GlobeNewswire May 5, 2023

NANOBIOTIX Provides Business Update and Reports Full Year 2022 Financial Results

GlobeNewswire April 24, 2023

NANOBIOTIX to Provide Operational Update and Report Full Year 2022 Financial Results on April 24, 2023

GlobeNewswire April 17, 2023

Voting Rights and Shares Capital of the Company

GlobeNewswire April 11, 2023

Nanobiotix to Postpone Full Year 2022 Financial Results and Conference Call

GlobeNewswire March 27, 2023

Nanobiotix to Provide Operational Update and Report Full Year 2022 Financial Results on March 28, 2023

GlobeNewswire March 14, 2023

Voting Rights and Shares Capital of the Company

GlobeNewswire February 14, 2023

Voting Rights and Shares Capital of the Company

GlobeNewswire January 11, 2023

NANOBIOTIX Announces First Patient Randomized in the United States in Global Phase 3 Pivotal Trial Evaluating Radioenhancer NBTXR3 in Head and Neck Cancer

GlobeNewswire December 27, 2022

NANOBIOTIX Announces Termination of Liquidity Contract and Publishes End of Contract Statement

GlobeNewswire December 21, 2022